DXR
Daxor Corporation
Healthcare — Medical Instruments & Supplies
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
None
2 analysts
$10.73
$-0.52 (-4.67%)
Target:
$22.50
(109.8%)
Price History
52-Week Range
Sign in to add DXR to a watchlist or set price alerts.
Fundamentals
| Market Cap | $61.30M |
| P/E Ratio (TTM) | 6.40 |
| Forward P/E | - |
| EPS (TTM) | $1.64 |
| Dividend Yield | - |
| Profit Margin | 34359.16% |
| Revenue Growth | -82.60% |
| ROE | 22.45% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $22.50 |
| Analysts | 2 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 57.0 |
| Beta | 0.26 |
| SMA 20 | $10.53 |
| SMA 40 | $10.29 |
| 52-Week High | $14.76 |
| 52-Week Low | $8.56 |
| 50-Day Avg | $10.33 |
| 200-Day Avg | $11.61 |
| Avg Volume | 4.0K |
| Volume | 809 |
Performance Analysis
BULLISHDXR shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 35% of its 52-week range.
+
RSI at 57.0 shows positive momentum.
+
P/E of 6.4 suggests the stock may be undervalued.
-
Revenue declined 82.6% year-over-year.
+
Healthy profit margin of 34359.2%.
~
Wall Street consensus is "none" from 2 analysts.
+
Average analyst target of $22.50 implies 109.8% upside.
Recent News
Loading news...
Last updated: Aug 01, 2026 04:13 UTC
Back to Screener Export Report